Drugs Similar to Semaglutide: Everything in the Same Class & How They Compare

Drugs Similar to Semaglutide: Everything in the Same Class & How They Compare

Semaglutide isn't the only option anymore.

Key Takeaways

• Same receptor, different outcomes: All drugs in this class activate the GLP-1 receptor, but weight loss ranges from ~8% (liraglutide) to 22.5% (tirzepatide). Mechanism details and half-life drive the difference.
• Tirzepatide is the upgrade: Adding GIP receptor agonism to GLP-1R activation pushes average weight loss roughly 7–8 percentage points above semaglutide 2.4mg.
• Oral options now exist: Orforglipron (no fasting) and the Wegovy 50mg pill (30-minute fast required) both deliver ~14–15% weight loss without injections.
• Strongest cardiovascular data: Semaglutide (SELECT trial, 20% MACE reduction) and liraglutide (LEADER trial, 13% MACE reduction) have the most extensive cardiovascular outcomes evidence.
• "Similar" does not mean interchangeable: Each drug has a different titration schedule, dosing interval, and side effect window — switching requires clinical guidance, not a straight swap.

You are looking for something that works like semaglutide — or works better, or works without injections, or works when semaglutide stopped working for you. All of those scenarios have answers in 2026, but the answers are different depending on what specifically you need. This guide maps every drug in the semaglutide class, what distinguishes each one, and how to think about choosing between them.

What makes a drug "semaglutide-like"

Semaglutide works by activating the GLP-1 receptor — the binding site for glucagon-like peptide 1, a hormone that the gut releases after eating. GLP-1 receptor activation slows gastric emptying, tells the pancreas to release insulin proportionally to blood glucose, and signals brain centers in the hypothalamus and brainstem to reduce appetite and caloric intake. Any drug that achieves those effects by activating the same receptor is, in the relevant clinical sense, semaglutide-like — regardless of whether it is a peptide, a small molecule, or a dual agonist.

The drugs in this category differ on four dimensions that matter clinically: how long they activate the receptor (half-life), whether they also activate other receptors (dual/triple agonism), how they are delivered (injection vs. pill), and how much weight loss they produce in trials. Working through each drug on those four dimensions is how you distinguish them.

Liraglutide (Victoza/Saxenda): the original long-acting option

Liraglutide was the first long-acting GLP-1 receptor agonist to reach major commercial scale. It shares semaglutide's core mechanism — fatty-acid modification for albumin binding, resistance to DPP-4 degradation — but its half-life is ~13 hours versus semaglutide's ~7 days. That shorter half-life requires daily injection rather than weekly, and it means the GLP-1 receptor is less continuously activated, which translates directly to lower weight loss: ~8% at 56 weeks for the 3mg obesity dose (SCALE trial) versus semaglutide's ~15% at 68 weeks.

The LEADER trial (9,340 participants, 3.8 years median follow-up) established liraglutide's cardiovascular outcome credentials: 13% reduction in MACE at the 1.8mg diabetes dose. That long-term safety dataset is something newer agents are still accumulating. Liraglutide remains in active use mainly for patients where cost or access favors it, and for those who specifically want the established LEADER data.

Dulaglutide (Trulicity): weekly, but not for obesity

Dulaglutide uses a different engineering approach — it is fused to an antibody fragment (Fc) rather than using fatty acid modification — to achieve once-weekly dosing. Its half-life is approximately 4–5 days. The primary FDA indication is type 2 diabetes, not obesity, and the weight loss seen in T2D trials (~3–5 kg above placebo) reflects that: dulaglutide was not optimized for weight loss the way Wegovy-dose semaglutide was. The AWARD-11 trial found the higher 3mg and 4.5mg doses produced more weight loss (~4.5 kg and ~5.1 kg respectively) but still well below semaglutide's obesity dose performance.

Dulaglutide is rarely the first choice when weight loss is the primary goal. Its clinical role is type 2 diabetes management in patients who want a once-weekly injection with a good tolerability profile and the REWIND cardiovascular outcomes trial behind it (12% MACE reduction at 5.4 years median follow-up).

Tirzepatide (Mounjaro/Zepbound): the semaglutide upgrade

Tirzepatide is the most direct answer to the question "what if I want more than semaglutide produces?" It adds GIP receptor agonism to GLP-1 receptor agonism — the dual mechanism is why its INN ends in "-patide" rather than "-glutide." The GIP receptor influences adipocyte function, fat cell sensitivity to insulin signaling, and possibly central appetite regulation through a pathway complementary to GLP-1. The combined signal produces 22.5% average body weight loss at 72 weeks (SURMOUNT-1, 15mg dose) — approximately 7–8 percentage points above semaglutide 2.4mg in the same population type. SURMOUNT-5, which compared tirzepatide directly against semaglutide 2.4mg, confirmed roughly that gap in a head-to-head design.

For patients whose primary goal is maximum weight loss from an approved injectable agent, tirzepatide is currently the top of the approved class. Its cardiovascular outcomes data (SURPASS-CVOT) showed a 17% reduction in MACE in T2D patients — strong data emerging for a relatively newer drug. It is once-weekly, like semaglutide.

Orforglipron (Foundayo): the needle-free semaglutide alternative

Orforglipron activates the GLP-1 receptor but is not a peptide — it is a small molecule. That structural difference means it can be taken as a standard once-daily pill with no fasting requirement, no special water volume restriction, and no injection. Phase 3 data showed approximately 14.7% weight loss at 36 weeks — in the same territory as semaglutide 2.4mg and well above liraglutide.

For needle-averse patients or those for whom injection logistics (storage, travel, injection technique) create adherence barriers, orforglipron represents the most practical option in the class currently. The side effect profile is qualitatively similar to semaglutide — nausea, vomiting, and diarrhea primarily during titration — but some patients report the peak GI effects are more manageable, possibly because small-molecule receptor binding kinetics differ from peptide agonists. Long-term cardiovascular outcomes data is not yet available for orforglipron to the extent it exists for semaglutide and liraglutide.

Oral semaglutide 50mg (Wegovy pill): semaglutide in a pill, with conditions

Oral semaglutide 50mg delivers the same molecule as injectable Wegovy, just via SNAC technology that allows a small fraction (~1%) to be absorbed through the gastric mucosa before stomach proteases destroy it. OASIS 1 showed ~15% weight loss at 68 weeks — comparable to injectable Wegovy when dosing conditions are observed. The conditions are non-trivial: empty stomach, no more than 120mL of water, 30 minutes before eating or taking other oral medications. Consistent adherence to those conditions is what determines whether the oral form performs comparably to the injection.

The key comparison with orforglipron: if you want an oral GLP-1 drug, orforglipron requires no fasting and can be taken with a full meal. The Wegovy pill achieves the same outcome but demands a morning ritual that some patients find disruptive. The two drugs represent two different approaches to the same "I don't want to inject" preference.

Exenatide (Byetta/Bydureon): the first-generation option

Exenatide came first — it was the original GLP-1 receptor agonist approved in the United States (2005). Derived from exendin-4, a peptide in Gila monster saliva, it activates the GLP-1 receptor without being structurally identical to human GLP-1. The twice-daily Byetta formulation is short-acting: peak effect on post-meal glucose, minimal sustained appetite suppression, ~2–3 kg weight loss above placebo. Bydureon (extended-release microsphere weekly formulation) achieves once-weekly dosing but through a slow-release delivery mechanism rather than the drug's intrinsic half-life, and weight loss is ~3–4 kg — below the modern standard.

Exenatide remains available and is used in some T2D patients who are on stable therapy and where cost or institutional preference drives the choice, but it is rarely initiated for new patients when semaglutide or tirzepatide are accessible.

How to choose: a framework by goal

What "semaglutide-like" does not mean

None of these drugs are interchangeable in the way that, say, generic versions of the same molecule are. Switching from semaglutide to tirzepatide is not simply an upgrade — it involves a new titration schedule from the lowest dose, exposure to a receptor pathway (GIP) your body has not encountered in a pharmacological context, and potentially different side effect timing. The same applies to moving from an injectable to an oral agent: orforglipron has different kinetics from semaglutide despite targeting the same receptor, and the body's response during titration may differ.

Dosing intervals differ in ways that matter practically: daily versus weekly injections affect how patients structure their routines, what happens when they miss a dose, and how side effects distribute across the week. A missed dose of Saxenda (daily) is clinically irrelevant; a missed dose of Wegovy (weekly) requires guidance on whether to take the missed dose or skip to the next scheduled one. These are not trivial practical differences.

One real limitation of the entire class: weight is regained after stopping. The STEP 4 trial showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year of stopping. This is not a deficiency unique to any individual drug — it reflects that GLP-1 receptor agonism alters active hormonal signaling that controls appetite, and removing the drug removes the signal. Choosing among these drugs means choosing a long-term treatment, not a course of medication with a planned endpoint.

Frequently Asked Questions

Is tirzepatide better than semaglutide for everyone?
On average weight loss data, tirzepatide outperforms semaglutide 2.4mg by ~7–8 percentage points. But "better" depends on the individual's tolerance, access, cost situation, and whether the GIP receptor pathway adds benefit for that person specifically. Some patients experience more GI side effects with tirzepatide's dual activation; others find the extra weight loss worth it.

Can you take two of these drugs at the same time?
No. Combining two GLP-1 receptor agonists does not provide additive benefit and significantly increases the risk of side effects. You use one agent at a time.

What if semaglutide stopped working?
Weight loss with GLP-1 RAs typically plateaus at 6–12 months as a new equilibrium is reached. If weight loss stalls at a level below the goal, the options are increasing to the maximum approved dose (if not already there), adding an additional mechanism (stepping up to tirzepatide), or addressing adherence and lifestyle factors that may be limiting response. True pharmacological tolerance to semaglutide is not well-documented.

Is compounded semaglutide still available?
Compounded semaglutide availability depends on current FDA shortage status and state-specific pharmacy regulations, which change over time. When Wegovy has been on the FDA shortage list, compounding pharmacies have been able to produce semaglutide formulations. When it is removed from the shortage list, compounding regulations tighten. Status should be checked against current FDA guidance, as this is an area that evolves frequently.

How is orforglipron different from semaglutide if they both activate the GLP-1 receptor?
Orforglipron is a small molecule, not a peptide. It fits into the GLP-1 receptor through a different binding mode and has no structural similarity to GLP-1. Because it is not a peptide, it survives digestion and requires no special delivery — which is why it can be a standard once-daily pill. Both drugs activate the same receptor and produce similar weight loss, but the molecular mechanism by which they reach that receptor is entirely different.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.